Figure 2. Differences between CD8+ T cells subsets of healthy people and ccRCC patients. We collected clinical data and bioinformatics data of peripheral CD8+ T cells and analyzed differences. (A) Gene chip tested differential genes of CD8+ T cells from peripheral blood of 5 healthy people and 5 ccRCC patients. (B) Pathways enrichment of different gene between healthy group and ccRCC group. (C, D) Differential gene enriched pathways of CD8+ T cells after co-cultured with/without RAG cells. (E, F) Proportion of CD8+CD25+ T cells (E) and CD8+CD28+ T cells of CD8+ T cells from healthy people (n = 350) and ccRCC patients (n = 274) (F). (G, H, I) Survival time of ccRCC patients with different level of activated CD8+ T cells (CD25+CD8+ T cells), activated CD8+ T cells (CD25+CD8+ T cells) and effector memory CD8+ T cells (CD45RO+CD62L-CD8+ T cells). Means ± SEM of experiment performed in triplicates are shown. *P < 0.05; **p < 0.005; ***p < 0.005; ns, not significant.